Natco Pharma shares closed at 883.20 on February 13, 2025 (NSE) and has given -39.46% returns over the last 6 months. Reported Standalone quarterly numbers for Natco Pharma are: Net Sales at Rs 407.60 crore in December 2024 down 34.82% from Rs. 625.30 crore in 2023. EBITDA stands at Rs. 197.40 crore in January 2024 down 26.29% from. Rs. 267.80 crore in Dec 2023, according to the company. Natco pharma EPS has decreased to Rs. 6.97 in December 24, 2024 from £10.72 in December 2023 and is down 0.18% over last 12 months. The company has a market capitalization of Rs. 1,292.60 crores (or $2.3 billion) and a market value of £1.2 billion. The firm has a shareholding of £2.1 billion ( or $3.4 billion) as of January 24, 2025, which is less than a quarter of the value of the company as of Dec 23, 2023 (or a quarter less than $2 billion). The company’s share price has fallen 0.20% in the last six months and 0.24% over the past 12 months, respectively. The stock is trading at a discount of 0.70% to the S&P BSE/CSE 100 index.
